Obinutuzumab news

All news on Obinutuzumab (also known as Gazyva and Gazyvaro): plants, production capacities, investments and involved companies.

3 November 2025
Roche's Gazyva Shows Significant Disease Reduction in Lupus Study
Phase III study shows Gazyva meets primary and secondary endpoints in SLE, potentially setting a new care standard by targeting B cells and reducing organ damage risk.
28 October 2025
Roche's Gazyva Shows Positive Phase III Results in Pediatric Nephrotic Syndrome
Gazyva achieved sustained remission in young nephrotic syndrome patients, reducing steroid use. No new safety issues. Data to be shared with health authorities.
20 October 2025
Roche's Gazyva Approved by FDA for Lupus Nephritis Treatment
FDA approves Gazyva for lupus nephritis, showing superior results in trials, offering a new treatment option to prevent kidney disease progression.
17 October 2025
Roche's Gazyva/Gazyvaro Gains EU CHMP Nod for Lupus Nephritis
CHMP backs Gazyva/Gazyvaro for lupus nephritis, showing superior renal response in trials. Awaiting European Commission decision.

Who will be producing Obinutuzumab in the future?

Find out with chemXplore Analytics